Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$25.93 – $37.15
46% from low
Sector
Asset Management
Exchange
NASDAQ
ETF
Roundhill considers weight loss medications, particularly GLP-1 agonists, to be among the most groundbreaking innovations currently reshaping the global pharmaceutical landscape. This conviction underpins the Roundhill GLP-1 & Weight Loss ETF (OZEM), which is distinguished as the world's inaugural ETF exclusively focused on the GLP-1 and broader weight management sector. Notably, OZEM employs an active management approach.
www.roundhillinvestments.com/etf/ozemNo one on the platform currently holds OZEM.
No tracked institution reports a position in OZEM as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2025-12-30 | $0.4099 | 2025-12-31 |
| 2024-12-30 | $0.0531 | 2024-12-31 |
No one on the platform has traded OZEM yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Analyst estimates unavailable for this ticker.
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| OZEMRoundhill Investments - GLP-1 & Weight Loss ETF | $31.06 | -1.05% | $40M | — |
| CEFZRiverNorth Active Income ETF | $8.01 | -0.44% | $39M | — |
| FLAXFranklin FTSE Asia ex Japan ETF | $35.83 | -0.63% | $55M | — |
| HOMZHoya Capital Housing ETF | $42.89 | -1.04% | $35M | — |
| KEMQKraneShares Public-Private Emerging Markets Internet and Technology ETF | $24.88 | -0.72% | $25M | — |
| NBJPNeuberger Berman Japan Equity ETF | $35.54 | -0.93% | $43M | — |
| NIXTResearch Affiliates Deletions ETF | $33.63 | -0.51% | $40M | — |
Source: Financial Modeling Prep · peers by sector/industry
Roundhill considers weight loss medications, particularly GLP-1 agonists, to be among the most groundbreaking innovations currently reshaping the global pharmaceutical landscape. This conviction underpins the Roundhill GLP-1 & Weight Loss ETF (OZEM), which is distinguished as the world's inaugural ETF exclusively focused on the GLP-1 and broader weight management sector. Notably, OZEM employs an active management approach.
Top constituents
top 25 · 100% of the fund
NVO Stock: Why Morgan Stanley Is Bearish On Novo Nordisk Despite Its Weight-Loss Drug Opportunity $NVO $LLY $OZEM https://stocktwits.com/news/equity/markets/nvo-stock-why-morgan-stanley-is-bearish-on-novo-nordisk-despite-its-weight-loss-drug-opportunity/cZtXhhNRBGl
View on StockTwits ↗Eli Lilly CEO Says $25B Deal Spree Is About Building Growth Beyond Obesity Into 2030s — ‘Not All These Bets Will Pay Off’ $LLY $OZEM $NVO https://stocktwits.com/news/equity/markets/eli-lilly-ceo-says-25-b-deal-spree-is-about-building-growth-beyond-obesity-into-2030s-not-all-these-bets-will-pay-off/cZYzbyERJsH
View on StockTwits ↗Mounjaro Vs Trulicity: Eli Lilly’s New FDA Win Puts Its Blockbuster Weight-Loss Drug In Focus $LLY $NVO $OZEM https://stocktwits.com/news/equity/markets/mounjaro-trulicity-eli-lilly-new-fda-win-weight-loss-drug-in-focus/cZYAeozRJAk
View on StockTwits ↗LLY Stock In Spotlight After Study Shows Zepbound Use Linked To Up To 38% Lower Healthcare Costs In Adults Above 55 Years $LLY $OZEM https://stocktwits.com/news/equity/markets/lly-stock-in-spotlight-after-study-shows-zepbound-use-linked-to-up-to-38-lower-healthcare-costs-in-adults-above-55-years/cZYNvzVRJYN
View on StockTwits ↗Novo Nordisk Begins New Study Testing Smaller Doses Of Blockbuster Wegovy – A Look At Some Key Highlights $NVO $LLY $OZEM https://stocktwits.com/news/equity/markets/novo-nordisk-looks-to-expand-wegovy-pill-push-with-lower-dose-study/cZYdgkhRJkA
View on StockTwits ↗$LLY $OZEM $SPY where you guys getting that good good “Reta”
View on StockTwits ↗Eli Lilly Steps Up Retatrutide Crackdown With Six New Lawsuits – CMO Hyman Says Drug Sold In Black Market Is ‘Not A Medicine’ $LLY $OZEM https://stocktwits.com/news/equity/markets/eli-lilly-steps-up-retatrutide-crackdown-with-six-new-lawsuits-cmo-hyman-says-drug-sold-in-black-market-is-not-a-medicine/cZo8cvERJgr
View on StockTwits ↗Citi Says Hims & Hers’ Full-Year Outlook Indicates ‘Hefty’ Q4 Earnings Lift, Warns Of Execution Risks $HIMS $OZEM https://stocktwits.com/news/equity/markets/citi-says-hims-and-hers-full-year-outlook-indicates-hefty-q4-earnings-lift-warns-of-execution-risks/cZoNbc5RJQC
View on StockTwits ↗Eli Lilly’s GLP-1 Pill Secures First European Milestone – Here’s Everything To Know About UK MHRA’s Foundayo Approval $LLY $OZEM https://stocktwits.com/news/equity/markets/lilly-foundayo-glp-uk-approval-lly-stock/cZojxJIRJfe
View on StockTwits ↗Eli Lilly CEO Bets On Weight-Loss Medicine Retatrutide As Next Growth Driver, Says Firm’s Future Has ‘Never Been Brighter’ $LLY $OZEM https://stocktwits.com/news/equity/markets/eli-lilly-ceo-bets-on-weight-loss-medicine-retatrutide-as-next-growth-driver-says-firm-future-has-never-been-brighter/cZo4Ax8RJI8
View on StockTwits ↗NVO Stock Slumps After Late-Stage Trial Fails Primary Goal – Retail Says ‘Current Revenue Drivers’ Still Intact $NVO $OZEM https://stocktwits.com/news/equity/markets/nvo-stock-slumps-after-late-stage-trial-fails-primary-goal-retail-says-current-revenue-drivers-still-intact/cZN4B0qRJPh
View on StockTwits ↗@getshorty77 I like $OZEM because it gives me to domestic and international stocks that are directly involved with GLP-1 innovation, plus it’s actively managed.
View on StockTwits ↗$OZEM New to this. Is there truly a benefit to owning it over the best pharma brand producing them?
View on StockTwits ↗Novo Nordisk Reportedly Escalates Legal Battle Against Eli Lilly – Even As Analysts See LLY Leading The GLP-1 Race $NVO $LLY $OZEM https://stocktwits.com/news/equity/markets/novo-nordisk-reportedly-escalates-legal-battle-against-eli-lilly-even-as-analysts-see-lly-leading-the-glp-1-race/cZZYsGBR7y1
View on StockTwits ↗Eli Lilly Moves Closer To Another Weight-Loss Drug: Retatrutide Clears Two More Phase 3 Trials Ahead Of FDA Filing $LLY $NVO $OZEM https://stocktwits.com/news/equity/markets/eli-lilly-moves-closer-to-another-weight-loss-drug-retatrutide-clears-two-more-phase-3-trials-ahead-of-fda-filing/cZZnFXJR7xA
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.